Research programme: allergy/immunology - Kyorin

Drug Profile

Research programme: allergy/immunology - Kyorin

Latest Information Update: 24 Feb 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical; Scottish Biomedical
  • Class
  • Mechanism of Action Immunomodulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Hypersensitivity; Immunological disorders; Respiratory tract disorders

Most Recent Events

  • 24 Feb 2009 Preclinical development is ongoing in Scotland
  • 26 Sep 2006 This programme is still in active development
  • 07 Dec 2000 Preclinical development for Allergy in Scotland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top